SCHEMBL6204007

SCHEMBL6204007

c1ccc(-c2csc(-n3nnc4ccccc43)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.51
MAPT P10636 6/20 0.51
HSD17B10 Q99714 4/20 0.50
AR P10275 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
TP53 P04637 4/20 0.49
ALOX15 P16050 3/20 0.49
ALDH1A1 P00352 4/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 7/20 0.47
KMT2A Q03164 7/20 0.47
KDM4E B2RXH2 4/20 0.47
TDP1 Q9NUW8 3/20 0.47
CYP3A4 P08684 2/20 0.47
HPGD P15428 2/20 0.47
BRCA1 P38398 2/20 0.47
NPC1 O15118 4/20 0.46
CYP1A2 P05177 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CYP2C9 P11712 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2848833 0.77 PTGER1 (0.56) CYP1A2CYP2C9CYP2C19
SCHEMBL7165417 0.72 JAK2 (0.68) RAB9AMAPTHSD17B10ARSMN1; SMN2
SCHEMBL6203912 0.71 SMN1; SMN2 (0.43) RAB9AMAPTHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL18674670 0.69 AR (0.84) RAB9AMAPTHSD17B10ARSMN1; SMN2
SCHEMBL8798821 0.69 AR (0.61) RAB9AMAPTHSD17B10ARSMN1; SMN2
SCHEMBL16614107 0.69 SMN1; SMN2 (0.58) RAB9AMAPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL8414958 0.69 RAB9A (0.54) RAB9AMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL25329191 0.69 RAB9A (0.59) RAB9AMAPTHSD17B10ARSMN1; SMN2
SCHEMBL15096790 0.69 PTGER1 (0.59) RAB9AMAPTARSMN1; SMN2MEN1
SCHEMBL165333 0.68 SMN1; SMN2 (0.71) RAB9AMAPTSMN1; SMN2TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1247810-B1 Novel benzotriazoles anti-inflammatory compounds PFIZER PROD INC (US) 2005-09-07 EP disclosed
US-6664395-B2 Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia PFIZER INC 2003-12-16 US disclosed
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds PFIZER INC. 2003-04-24 US disclosed
EP-1247810-A1 Novel benzotriazoles anti-inflammatory compounds Pfizer Products Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078432-A1 Novel benzotriazoles anti-inflammatory compounds MAPK1, JAK1, RUNX1 RAB9A 3414/4885MAPT 2726/4885HSD17B10 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.